ArticleCNS neuroscience & therapeutics2025
Plasma Metabolites Link Non-Communicable Diseases to Increased White Matter Hyperintensities.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiome-immune-metabolic mechanisms in cerebrovascular disease: evidence-graded insights from cerebral small vessel disease, ischemic stroke, and intracerebral hemorrhage.Frontiers in microbiology · 2026Review
- Plasma Metabolites Link Non-Communicable Diseases to Increased White Matter Hyperintensities.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsCerebral small vessel disease (CSVD) and non-communicable diseases (NCDs) are major global health burdens. White matter hyperintensities (WMH) are a key imaging feature of CSVD, but the relationship between WMH and NCDs, especially the role of plasma metabolites in this association, remains unclear. This study aims to elucidate this link.
methodsThis study included participants with WMH from the UK Biobank cohort and examined the prevalence of 29 common NCDs in this population. General linear regression was used to analyze the association between NCDs and WMH. Propensity score matching and elastic net regression identified plasma metabolites associated with NCDs. Mediation analysis was conducted to explore the role of these metabolites in the association between NCDs and WMH.
resultsA total of 44,630 participants were included, of whom 47.0% were male. Approximately one-third of the participants had NCDs, with the most common being hypertension, dyslipidemia, and asthma. Compared to those without NCDs, the WMH volume in individuals with one or more comorbid NCDs was significantly increased by 18.43% to 68.15%. During a median follow-up of 9.5 years, individuals with hypertension, obstructive sleep apnea, and hypertension combined with coronary ischemic heart disease had significantly larger WMH volumes compared to those without NCDs, with increases of 30.81%, 36.44%, and 36.75%, respectively. Further analysis revealed that plasma metabolites associated with NCDs mediated this risk.
conclusionsThis study elucidated the association between WMH and NCDs, showing that common NCDs significantly increase WMH volume. Plasma metabolites associated with NCDs mediate this risk. This provides new insights into preventing WMH progression in individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.